Upjohn lazaroid R&D
Executive Summary
FDA Commissioner Young told recent gathering in Washington D.C. he was "pleased" to hear that Upjohn might consider a Treatment IND for lazaroid R&D compounds. Senior VP Mark Novitch told analysts in December that Upjohn might use the Treatment IND procedure if the neuroprotective products showed promise during early clinical trials ("The Pink Sheet" Jan. 4, p. 10). Commenting on Novitch's remarks, Young said: "I was pleased to see the interest in . . . the Treatment IND . . . and the quoting of Mark Novitch and others talking about this as an opportunity. I think it is.".